IFF Launches Omni-Bos™ PHY to Help Dairy Producers Get More Value from Feed

 New phytase technology unlocks nutrients already present in feed to improve efficiency, profitability and sustainability

(BUSINESS WIRE) -- IFF (NYSE: IFF) — a global leader in flavors, fragrances and health and biosciences — today announced the launch of Omni-Bos™ PHY, a novel phytase enzyme designed specifically for dairy cattle. The technology helps producers improve nutrient utilization and feed efficiency by unlocking nutrients already present in feed, enabling cows to derive greater value from existing feed ingredients. Omni-Bos™ PHY will initially launch in the Middle East, Africa and Asia-Pacific regions.

“We believe the future of dairy nutrition is helping cows receive more value from the nutrients in their feed,” said Regina Cortada, vice president, Animal Nutrition & Health for IFF Health & Biosciences. “Our research challenged the long-held assumption that dairy cows fully utilize the phytate contained in feed. We found that phytate breakdown is often incomplete, leaving valuable nutrients unavailable to the animal. Omni-Bos PHY was developed to unlock those nutrients and help producers improve feed efficiency, support sustainability goals and increase profitability.”

Global milk production is projected to grow 2% annually over the coming decade, increasing pressure on producers to improve productivity while managing feed costs and sustainability targets. Feed remains one of the largest expenses in dairy production, making nutrient efficiency a critical opportunity for producers seeking to improve profitability and performance.

Phytate — a naturally occurring compound found in many feed ingredients — can bind nutrients and reduce their availability to the animal. While phytase technology has been widely used in poultry and swine production for decades, its effectiveness in dairy cattle has historically been limited.

“Traditional phytase enzymes were not designed to withstand the unique digestive conditions of dairy cattle,” said Ester Vinyeta, innovation director, Animal Nutrition & Health for IFF Health & Biosciences. “Omni-Bos PHY was specifically developed for ruminants and is designed to remain active where it can unlock nutrients that would otherwise remain inaccessible. This enables dairy producers to extract more nutritional value from existing feed ingredients while reducing nutrient losses.”

By helping cows utilize more of the protein, phosphorus and minerals already present in feed, Omni-Bos™ PHY can reduce reliance on supplemental phosphorus and protected amino acids while supporting the use of alternative protein sources. The result is improved feed efficiency, lower feed costs and reduced nitrogen and phosphorus excretion.

The enzyme is suitable for use in concentrates, premixes and total mixed rations and has been evaluated extensively throughout product development. In one study, Omni-Bos™ PHY decreased undegraded phytate in the abomasum by approximately 70% compared with a control diet. Additional studies in lactating dairy cows demonstrated that Omni-Bos™ PHY:

Improved phosphorus and phytate digestibility

Reduced nitrogen and phosphorus excretion

Increased digestibility of nutrients including crude protein and calcium

Collectively, these findings demonstrate Omni-Bos™ PHY’s ability to improve nutrient utilization and help dairy producers maximize the value of every ton of feed while supporting more sustainable production systems.

To learn more about Omni-Bos PHY, visit https://www.iff.com/animal-nutrition/products/omni-bos-phy

Welcome to IFF

At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in taste, scent and biosciences, we’re innovating for the future. We deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook.

©2026 International Flavors & Fragrances Inc. (IFF). IFF, the IFF Logo, and all trademarks and service marks denoted with ™, ℠ or ® are owned by IFF or affiliates of IFF unless otherwise noted. All Rights Reserved.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260916599752/en/

Permalink

https://aetoswire.com/en/news/1709202657391

Contacts

Paulina Heinkel

VP, Branding and Communication for IFF Health & Biosciences

media.request@iff.com

Galderma’s Restylane® Volyme™ Demonstrates High Effectiveness, Satisfaction and a Robust Safety Profile in Chinese Patients With Temple Hollowing

ZUG, Switzerland - Wednesday, 16. September 2026


    Positive topline results showed that Restylane Volyme (known as Restylane Contour in the U.S.) was highly effective in the correction of moderate-to-severe temple hollowing, with high responder rates maintained through Month 121
    Restylane Volyme was well tolerated, with no incidences of granulomas. Patient and investigator satisfaction were also high1
    These data support Galderma’s aim to expand the availability of the Restylane portfolio in China – a market undergoing significant expansion, and further strengthen Restylane’s vast clinical evidence base2,3

 

(BUSINESS WIRE)--Galderma (SIX: GALD) today announced positive topline results from a study of Restylane Volyme for the correction of moderate-to-severe temple hollowing in 162 patients in China.1 The study met its primary endpoint, demonstrating the effectiveness and safety of Restylane Volyme versus a no-treatment control, while also achieving high patient and investigator satisfaction.1 These data further reinforce Galderma's ambition to expand its Restylane hyaluronic acid (HA) injectables portfolio in China, one of the world's fastest-growing aesthetics markets, through evidence generation that supports broader patient access and additional treatment areas.1-3

Powered by diverse NASHA®, NASHA HD™, and OBT™ technologies, Restylane offers gels with the highest firmness to the highest flexibility, enabling personalized treatments that deliver structural support, natural-looking results, and a healthy glow.1,4-8 Restylane Volyme is a moderately soft and flexible gel made with OBT that distributes within the tissue to offer natural-looking results, helping to soften temple hollowing, restore facial balance, and create a refreshed appearance.1,4,9 With a dual-layer patent-pending technique leveraging both needle and cannula, Restylane Volyme enables healthcare professionals to provide precise, customized, and safe product placement in line with each patient’s aesthetic goals10-12

The volume of the temples can diminish with age, which can disrupt facial balance and harmony, and contribute to a tired, sunken, and aged appearance.12-14 These facial changes can be accelerated in people undergoing medication-driven weight loss, a phenomenon which has increased rapidly in recent years.12-14 Following the launch of Restylane Volyme in China for the treatment of the mid-face region, this study provides new evidence supporting its effectiveness and safety for correction of temple hollowing, in a market where there are currently limited options.1

“Temple hollowing is a common concern among patients seeking facial rejuvenation, particularly for those experiencing medication-driven weight loss, yet treatment options in China remain limited. These results demonstrate that Restylane Volyme can provide effective, natural-looking correction with high levels of patient satisfaction and a robust safety profile. As demand for individualized aesthetic treatments continues to grow in China, expanding the range of evidence-based solutions available will be increasingly important.”

PROF. ZHAO HONGYI
STUDY PRINCIPAL INVESTIGATOR,
DIRECTOR & CHIEF OF THE DEPARTMENT OF PLASTIC SURGERY, BEIJING HOSPITAL, CHINA

In this randomized, evaluator-blinded study, 162 adults were recruited across six sites in China and were split 2:1 into two groups; the Restylane Volyme treatment group or the no treatment control group.1 Results showed that for patients in the Restylane Volyme group:

    Strong effectiveness
        94.4% of patients demonstrated at least 1-grade improvement in temple hollowing, from baseline, in both temples at Month 6 after last treatment, compared to just 2.0% in the control group at Month 6 after baseline.1
        Blinded-evaluator Galderma Temple Volume Deficit Scale responder rates remained high through Month 121
        91.3% of patients showed improvement on the Global Aesthetic Improvement Scale for both temples through Month 12, according to the treating investigator1
    High satisfaction
        Patient satisfaction was high at Month 3 and remained consistently high, with more than 84% of patients satisfied with both the natural look and natural feel of their temples through Month 121
        More than 90% said they would recommend the treatment to a friend, and over 86% would have the treatment again1
        Half of the participants felt comfortable returning to social engagement within 24 hours after initial treatment1
    Robust safety
        Restylane Volyme was generally well tolerated, with no treatment-related serious adverse events and no granulomas1

“These positive topline results further strengthen the clinical evidence supporting Restylane Volyme and mark an important step in our strategy to expand the Restylane portfolio in China. As one of the world’s fastest-growing aesthetics markets, China presents a significant opportunity to address evolving patient needs with science-backed, differentiated solutions. This study supports our ambition to broaden the indications available to practitioners and patients, while reinforcing Galderma’s leadership in Injectable Aesthetics through continued investment in innovation and clinical research.”

BALDO SCASSELLATI SFORZOLINI, M.D., PH.D.
GLOBAL HEAD OF R&D
GALDERMA

With over 30 years of innovation and more than 77 million treatments administered worldwide, the Restylane portfolio offers a versatile range of HA gels that remain highly relevant in responding to today’s most significant aesthetic trends and needs.15-16 China is one of the fastest growing aesthetics markets worldwide and HA fillers are among the top 10 most-sold aesthetics products.2,3 This study highlights Galderma’s commitment to expand the availability of its Restylane portfolio to more patients and practitioners in China and exemplifies its continuing expansion in a growing and strategically significant market.

About the Restylane portfolio
Restylane HA treatments are designed differently to go beyond volumizing for natural-looking results.17-19 Our HA is minimally modified and our innovative manufacturing process preserves its biocompatibility while creating individual products designed for a specific purpose.5,20,21 Powered by NASHA®, NASHA HD™, and OBT™ technologies, Restylane offers gels with the highest firmness to the highest flexibility, enabling personalized treatments that deliver structural support, natural-looking results, and a healthy glow.4,6-8 Trusted for almost three decades, our HA gels work in sync with your skin for 100% natural-looking results. 18,22,23 Approved indications vary by market.

About Galderma
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

References

    Galderma. Data on file. 43CH2401
    Deloitte. China Aesthetic Medicine Outlook Report. Accessed September 2026. Available online.
    Grand View Horizon. China Aesthetic Medicine Market Size & Outlook, 2026-2033. Accessed September 2026. Available online
    Galderma. Data on file. MA-56724. 2023. Global rheology data (xStrain and G´ including Restylane SHAYPE).
    Galderma. Data on file. MA-58650. Degree of modification of HA fillers.
    Nikolis A, et al. Effectiveness and Safety of a New Hyaluronic Acid Injectable for Augmentation and Correction of Chin Retrusion. J Drugs Dermatol. 2024;23(4):255–261. doi: 10.36849/JDD.8145.
    Öhrlund Å, et al. Differentiation of NASHA and OBT Hyaluronic Acid Gels According to Strength, Flexibility, and Associated Clinical Significance. J Drugs Dermatol. 2024;23(1):1332–1336. doi: 10.36849/JDD.7648.
    Belmontesi M, et al. Injectable Non-Animal Stabilized Hyaluronic Acid as a Skin Quality Booster: An Expert Panel Consensus. J Drugs Dermatol. 2018;17(1):83–88.
    Talarico S et al. High Patient Satisfaction of a Hyaluronic Acid Filler Producing Enduring Full-Facial Volume Restoration: An 18-Month Open Multicenter Study. Dermatol Surg. 2015;41(12):1361-9. doi: 10.1097/DSS.0000000000000549
    Restylane® Volyme. IFU. Available online. Accessed September 2026
    Galderma Laboratories, L.P. Data on file. MA-63365 Study Report. 2025
    Galderma. Data on file. Restylane Contour temple investigator closeout meeting executive summary. 2025
    Humphrey CD & Lawrence AC. Implications of Ozempic and other GLP-1 receptor agonists for facial plastic surgeons. Facial Plast Surg, 2023;39:719-73. doi: 10.1055/a-2148-6321
    Tay JQ. Ozempic face: A new challenge for facial plastic surgeons. JPRAS.2023;81-97-98. doi: 10.1016/j.bjps.2023.04.057
    Galderma. Data on file. MA-57232 [Updated]. 77 Million treated.
    Galderma. Data on file. MA-55607. Restylane® 27 years data publications analysis
    Restylane® EU Instructions for Use. July 2026.
    Di Gregorio C, et al. 25+ years of experience with the Restylane portfolio of injectable HA fillers for facial aesthetic treatment. E-poster presented at AMWC; March 27-29, 2024; Monaco.
    Galderma. Data on file. MA-48544 Subject satisfaction (GAIS) – NASHA and OBT Fillers. 2021.
    Kablik J, et al. Comparative physical properties of HA dermal fillers. Dermatol Surg. 2009; 35, 302–312. doi: 10.1111/j.1524-4725.2008.01046.x.
    Edsman K, et al. Gel properties of hyaluronic acid dermal fillers. Dermatol Surg. 2012;38:1170–1179. doi: 10.1111/j.1524-4725.2012.02472.x.
    Solish N, et al. Dynamics of hyaluronic acid fillers formulated to maintain natural facial expression. J Cosmet Dermatol. 2019;18(3):738-746. doi: 10.1111/jocd.12961.
    Philipp‐Dormston WG, et al. Perceived naturalness of facial expression after HA filler injection in nasolabial folds and lower face. J Cosmet Dermatol. 2020;19(7):1600-1606. doi: 10.1111/jocd.1320

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260915734207/en/

Permalink
https://www.aetoswire.com/en/news/1609202657354

Contacts

For further information:

Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50

Richard Harbinson
Corporate Communications Director
richard.harbinson@galderma.com
+41 76 210 60 62

Céline Buguet
Franchises and R&D Communications Director
celine.buguet@galderma.com
+41 76 249 90 87

Emil Ivanov
Head of Strategy, Investor Relations, and ESG
emil.ivanov@galderma.com
+41 21 642 78 12

Jessica Cohen
Investor Relations and Strategy Director
jessica.cohen@galderma.com
+41 21 642 76 43

Schneider Electric Concludes Innovation Summit Middle East & Africa, Highlights Energy Intelligence as the Next Phase of the Energy Transition

 Abu Dhabi, United Arab Emirates -

As AI, electrification and industrial expansion reshape energy demand across the Middle East and Africa, Schneider Electric today concluded Innovation Summit Middle East & Africa by positioning energy intelligence as the next phase of the energy transition - where infrastructure becomes more connected, resilient and software-defined.

Held at ADNEC in Abu Dhabi, the two-day summit convened over 2,500 attendees, including government leaders, industry analysts, customers, partners, students, and media, under the theme ‘Advancing Energy Tech to Power Intelligence and Resilience.’

Industry leaders explored how electrification, AI-ready data centers, cybersecurity, and digital innovation are reshaping energy systems. Day one featured keynotes from H. E. Abdullah bin Touq Al Marri, UAE Cabinet Member and Minister of Economy and Tourism, and Schneider Electric CEO Olivier Blum, in the presence of H.E. Marie Audouard, Ambassador Extraordinary and Plenipotentiary of the French Republic to the UAE. The summit also featured the launch of the Innovation Hub, the Data Cube, and Olivier Blum’s address on “The Era of Intelligence.”

“We’re entering an Era of Intelligence in which AI is becoming embedded in the physical economy. AI may be digital, but it runs on electricity and depends on the physical systems beneath it,” said Olivier Blum, CEO of Schneider Electric. “As an Energy Technology Partner, we help customers connect energy and operations through data, software, AI and automation, turning intelligence into action to improve performance, resilience and competitiveness. The scale of this shift is clear in the Middle East and Africa, where governments and businesses are investing in energy and digital infrastructure to support industrial transformation and long-term growth.”

The summit also featured the release of the company’s 2026 Industrial AI in CPG Study for the UAE, which found that 59% of UAE manufacturers expect transformational AI adoption by 2030, compared with 42.2% globally. Walid Sheta, President, MEA Zone, said, “As our region’s manufacturers move faster and more confidently on industrial AI than anywhere else, it’s our responsibility to make sure that confidence is well-founded. Cybersecurity, resilience, and return on AI investment are the concerns we hear about most often from customers, and rightly so.”

Schneider Electric reaffirmed its commitment to collaborating with governments, customers, and partners to accelerate intelligent, resilient energy infrastructure.

Permalink

https://www.aetoswire.com/en/news/1609202657358

Contacts

Press contact:

Mohammed Abdulla

mabdulla@apcoworldwide.com

www.se.com

Rubedo Life Sciences Announces Clinical Study to Treat Hair Loss with GPX4 Modulator RLS-1496, First Human Ex Vivo Evidence Demonstrates Robust Hair Follicle Growth

 MOUNTAIN VIEW, Calif. - Wednesday, 16. September 2026 AETOSWire  

AGA clinical trial to begin in Fall 2026 led by David Pariser, MD, FACP, FAAD, former President of the American Academy of Dermatology and Principal Investigator in more than 450 dermatology clinical trials

Rubedo’s RLS-1496, the first and only GPX4 modulator currently in clinical trials, demonstrates superior hair follicle restoration in human ex vivo androgenetic alopecia (AGA) model, matching or outperforming finasteride; findings consistent with dual SenoAdaptive mechanism that activates dormant hair follicle

 

(BUSINESS WIRE) -- Rubedo Life Sciences, Inc. (Rubedo) today announced a new clinical study of investigational RLS-1496 in patients with androgenetic alopecia (AGA), beginning October 2026, with initial data expected in the first half of 2027. The study marks the first-ever clinical evaluation of a GPX4 modulator in hair loss, extending the program that established RLS-1496 as the world’s first GPX4 modulator to enter human clinical trials of any kind.

RLS-1496 has already demonstrated efficacy in clinical trials for actinic keratoses and aging skin, and other skin conditions such as psoriasis and atopic dermatitis, generating novel human evidence demonstrating the dual SenoAdaptive mechanism that clears pathologic senescent cells and promotes a redox reset by modulating NRF2 pathways in stressed aged cells, including stem and progenitor cells. Ex vivo studies on a human hair follicles AGA model resulted in the restoration of hair follicle growth, as depicted in the image above.

In an independent ex vivo human AGA model — conducted using intact human hair follicles from male patients with AGA, challenged with dihydrotestosterone (DHT) to replicate the follicular miniaturization environment seen in AGA patients — RLS‑1496 demonstrated statistically and highly statistically significant increases in hair follicle elongation compared to vehicle control at 2 doses, respectively, with the highest dose showing a numerically greater trend in mean elongation than finasteride.

Hair follicle elongation at Day 6 was greater with RLS-1496 versus vehicle across all doses, with the strongest effect at the highest concentration — directionally outperforming standard-of-care finasteride

The pattern is consistent with rescue of the anagen (active growth) phase, when targeting senescent cells from the follicular niche allows stem cell reactivation from the dormant state and the follicle to resume its natural growth program

“The senescent cell biology underlying hair follicle aging is compelling, deeply consistent with what we have seen across our RLS-1496 program, and vastly underexplored as a therapeutic target,” said Rubedo Chief Executive Officer Frederick Beddingfield III, MD, PhD, FAAD. “For the first time, we are bringing a medicine into the clinic designed to clear the aged cells at the root of stem cell dormancy and follicular miniaturization. We are proud to do so in partnership with Dr. Pariser, and we are moving with the same urgency that made RLS-1496 the world’s first GPX4 modulator in human trials.”

AGA is the most prevalent form of hair loss globally, affecting approximately 50 million men and 30 million women in the U.S. alone; however, the treatment landscape has seen no genuinely new FDA-approved approaches in nearly 30 years.2 The global AGA market, valued at $3.2 billion in 2025 and projected to reach $6.8 billion by 2035, is defined by two therapies — minoxidil and finasteride — that slow the hormonal signals that cause hair follicles to progressively shrink and degenerate, a process known as follicular miniaturization. Follicular miniaturization is the biological hallmark of AGA, in which each successive growth cycle produces a thinner, shorter hair until the follicle can no longer produce visible hair. Neither therapy addresses the senescent — aged and dysfunctional — cells now understood to accumulate within the follicular niche and drive this miniaturization at the cellular level.3,4,5

Unlike existing therapies that target secondary hormonal causes of hair loss, RLS-1496 is designed to act on the primary cellular aging mechanism: the accumulation of senescent and stressed dermal papilla cells that actively suppress stem cells, follicular regeneration, and drive progressive miniaturization. By targeting these cells with selective elimination or functional restoration, depending on the cell state, RLS-1496, a first-in-class SenoAdaptive Drug, aims to remove the cellular brake on follicular regeneration itself.3,4,5,6

Rubedo Co-Founder and Chief Scientific Officer Marco Quarta, PhD, will present the ex vivo data, along with additional RLS-1496 data, at the 13th Annual Aging Research & Drug Discovery (ARDD) Meeting at Harvard University, October 1–3, 2026 — the world’s largest dedicated longevity science conference. The presentation marks the first time a GPX4 modulator program in hair loss will be presented at a major longevity science conference.

Dr. Quarta said, “RLS-1496 appears to act at several convergent points in the AGA disease cascade — where we believe it acts by clearing senescent cells, suppressing follicular regeneration, reducing inflammatory SASP signaling, while also modulating NRF2 pathways and activating Wnt/β-catenin pathways governing anagen re-entry. To our knowledge, no approved AGA therapy operates at this level of biology.”

Rubedo’s proprietary ALEMBIC™ spatial transcriptomics applied to patient hair follicle biopsies identified senescence markers and transcriptomic signals consistent with activation of the follicular regenerative cascade, including the expansion of hair follicle progenitors, and downregulation of key drivers of the follicle regression phase — providing human clinical evidence that RLS-1496’s effects on senescent cell biology extend to hair follicle tissue. In preclinical animal studies, RLS-1496 also achieved approximately 32% greater hair regrowth versus vehicle.1,6,7

“The preliminary data we have seen with RLS-1496 are scientifically intriguing and warranted clinical evaluation,” said Dr. Pariser, Professor of Dermatology at Eastern Virginia Medical School and Principal Investigator of Virginia Clinical Research, Inc., who will be leading the RLS-1496 hair loss clinical trial. “The senescence biology underlying AGA is increasingly well-supported in the published literature, and RLS-1496 represents a genuinely novel approach to it. I look forward to seeing what the data show in patients given the ongoing unmet need.”

About RLS-1496 and GPX4 Modulation

Rubedo’s lead candidate RLS-1496, being developed for topical and oral administration, is a first-in-class, disease-modifying GPX4 modulator selectively targeting pathologic senescent and other stressed, aging cells that drive chronic, age-dependent diseases. These include immunology and inflammation (I&I), dermatology and skin aging, hair loss, metabolic syndrome (obesity, diabetes, liver fibrosis), sarcopenia, and neurodegenerative disease.

In certain pathologic cells, aging is associated with an imbalance in GPX4. Modulation of GPX4 sensitizes cells to ferroptosis, which is a type of programmed cell death and is believed to be an Achilles heel of senescent cells. By modulating GPX4 in ferroptosis-sensitive senescent “aged” cells, RLS-1496 may be able to clear these cells to fight disease and also support healthy cells to function properly and restore tissue homeostasis. Beyond its targeted senolytic function in triggering selective ferroptosis within pathological senescent cells, RLS-1496 can also act as a restorative modulator that induces a vital ‘redox-reset’ through a controlled hormetic response in stressed neighboring cells, effectively clearing the source of chronic inflammation while actively re-establishing healthy tissue homeostasis. This dual-action mechanism represents a novel drug category—Adaptive SenoTherapeutics.

RLS-1496 uses Rubedo’s proprietary, AI-driven drug discovery platform ALEMBIC™, which identifies targets within pathologic senescent cells and develops selective cellular rejuvenation medicines for these targets.

About Rubedo Life Sciences

Rubedo Life Sciences is a clinical-stage biotech developing a broad portfolio of innovative selective cellular rejuvenation medicines targeting aging cells that drive chronic age-related diseases. Our proprietary AI-driven ALEMBIC™ drug discovery platform is developing novel first-in-class small molecules to selectively target pathologic and senescent cells, which play a key role in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic, and other chronic disorders, including hair loss. Our lead drug candidate – RLS-1496, a potential first-in-class disease-modifying GPX4 modulator – is currently in Phase I clinical trials. The Rubedo leadership team is composed of industry leaders and early pioneers in chemistry, AI technology, longevity science, and life sciences, with expertise in drug development and commercialization from both large pharmaceutical and leading biotechnology companies. The company is headquartered in Mountain View, CA, USA, and has offices in Milan, Italy. For additional information, visit www.rubedolife.com.

References

Rubedo Life Sciences. RLS-1496 demonstrates hair follicle elongation in a DHT-challenged ex vivo androgenetic alopecia model. Data on file. 2026.

Global Market Insights. Androgenetic Alopecia Treatment Market Size, Share & Trends Analysis Report. 2026

Bahta AW, Farjo N, Farjo B, Philpott MP. Premature Senescence of Balding Dermal Papilla Cells In Vitro Is Associated with p16(INK4a) Expression. Journal of Investigative Dermatology2008;128(5):1088-1094. doi: 10.1038/sj.jid.5701147

Yang YC, Fu HC, Wu CY, Wei KT, Huang KE, Kang HY. Androgen Receptor Accelerates Premature Senescence of Human Dermal Papilla Cells in Association with DNA Damage. PLoS ONE2013;8(11): e79434. doi: 10.1371/journal.pone.0079434

Upton JH, Hannen RF, Bahta AW, Farjo N, Farjo B, Philpott MP. Oxidative Stress-Associated Senescence in Dermal Papilla Cells of Men with Androgenetic Alopecia. Journal of Investigative Dermatology 2015;135(5):1244-1252. doi: 10.1038/jid.2015.28

Pappalardo A, Kim JY, Abaci HE, Christiano AM. Restoration of hair follicle inductive properties by depletion of senescent cells. Aging Cell2024;24: e14353. doi: 10.1111/acel.14353

Rubedo Life Sciences. RLS-1496 achieves 32% greater hair regrowth versus vehicle in preclinical animal studies. Data on file. 2026.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260916811892/en/

Permalink

https://www.aetoswire.com/en/news/1609202657361

Contacts

Investor Contact: Ali Siam, Chief Business Officer alisiam@rubedolife.com | 781-974-9559

Media Contact: Peter Collins, TogoRun p.collins@togorun.com | 908-499-1200

NetApp and Tampa Bay Buccaneers Partner to Enable Data-Driven Operational Excellence

 New sponsorship expands NetApp’s presence across the NFL, delivering trusted data, intelligence, and the ability to perform in critical moments

 

(BUSINESS WIRE)--NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced that they have been named an Official Partner of the Tampa Bay Buccaneers. This new relationship builds on NetApp’s status as the Official Intelligent Data Infrastructure Partner of the NFL, helping the league and its teams quickly and confidently access, manage, and activate their data. The Buccaneers will leverage NetApp technology to support the experience for Buccaneers fans in the stadium on game days and beyond.

“NetApp will serve as a trusted technology partner that will help us elevate the customer experience for all Buccaneers fans,” said Buccaneers Chief Commercial Officer Atul Khosla. “Reliable and secure access to data plays an essential role in the overall game day experience at Raymond James Stadium. NetApp’s industry-leading intelligent data infrastructure will help us deliver a more seamless and connected experience for our Krewe at games and across the digital platforms that we use.”

This partnership launches following the Buccaneers first regular 2026 season game against the Cincinnati Bengals on September 13. The partnership expands NetApp’s relationship with the NFL as the league’s Official Intelligent Data Infrastructure Partner, helping to securely manage, protect, and activate the data behind the league’s operations. Across the NFL, NetApp technology supports demanding real-world workloads, including the storage and availability of game day video used by NFL football operations and club football operations teams. This collaboration has demonstrated how the right infrastructure can help complex, data-intensive organizations operate more efficiently and resiliently.

By using NetApp Keystone, a flexible and simple subscription-based service that adapts to changing business needs, the Buccaneers can accelerate data workloads with industry-leading performance, intelligent data management, and high availability across data centers and cloud environments. The NetApp Platform delivers built-in data security that autonomously detects threats and enables rapid recovery.

“Successful teams achieve meaningful results long before game day by bringing together the right people, trusted data, sound decisions, and disciplined execution,” said Gabie Boko, Chief Marketing Officer at NetApp. “Elite sports show what organizations can accomplish when their people can turn information into confident action. As a Proud Partner of the Tampa Bay Buccaneers, we’re celebrating the preparation, trust, and teamwork that sustain excellence and the Intelligent Data Infrastructure that helps make it possible.”

Additional Resources

NetApp and the NFL Team Up with Intelligent Data Infrastructure

The Unseen MVP of the NFL Season

NetApp Named Presenting Partner of 2026 NFL Madrid Game

NetApp Data Platform Powers Data Operations for Super Bowl LX

About the Tampa Bay Buccaneers

The Tampa Bay Buccaneers are in their 51st season as members of the National Football League and compete in the National Football Conference’s South Division. They were purchased by the late Malcolm Glazer in 1995 and are currently owned by the Glazer Family. Established in 1976, the Buccaneers have totaled 10 division titles, two conference championships and two Super Bowl Championships, including Super Bowl LV that was played on their home field at Raymond James Stadium. The Buccaneers have also been leaders in the NFL in fan engagement, earning a record 12 consecutive No. 1 rankings in overall customer satisfaction in the league’s annual Voice of the Fan survey. Additionally, the franchise is very active in the community, with the Tampa Bay Buccaneers Foundation, the Glazer Vision Foundation and the Glazer Family Foundation. For more information, visit www.buccaneers.com.

About NetApp

For more than three decades, NetApp has helped the world’s leading organizations navigate change – from the rise of enterprise storage to the intelligent era defined by data and AI. Today, NetApp is the Intelligent Data Infrastructure company, helping customers turn data into a catalyst for innovation, resilience, and growth.

At the heart of that infrastructure is the NetApp data platform – the unified, enterprise-grade, intelligent foundation that connects, protects, and activates data across every cloud, workload, and environment. Built on the proven power of NetApp ONTAP, our leading data management software and OS, and enhanced by automation through the AI Data Engine and AFX, it delivers observability, resilience, and intelligence at scale.

Disaggregated by design, the NetApp data platform separates storage, services, and control so enterprises can modernize faster, scale efficiently, and innovate without lock-in. As the only enterprise storage platform natively embedded in the world’s largest clouds, it gives organizations the freedom to run any workload anywhere with consistent performance, governance, and protection.

With NetApp, data is always ready – ready to defend against threats, ready to power AI, and ready to drive the next breakthrough. That’s why the world’s most forward-thinking enterprises trust NetApp to turn intelligence into advantage.

Learn more at www.netapp.com or follow us on X, LinkedIn, Facebook, and Instagram.

NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260916768662/en/

Permalink

https://aetoswire.com/en/news/1609202657360

Contacts

Media Contact:  

Kenya Hayes  

NetApp  

kenya.hayes@netapp.com  

Investor Contact:  

Kris Newton  

NetApp  

kris.newton@netapp.com  

 

The Opening of Jayasom Wellness Resort Advancing AMAALA’s Wellness Vision

 RIYADH, Saudi Arabia - 

The latest addition to AMAALA’s wellness ecosystem integrates evidence-based practices with Arab and Eastern healing practices complemented by personalized wellness programs

 

(BUSINESS WIRE)--Red Sea Global (RSG), the regenerative tourism developer, has opened Jayasom Wellness Resort AMAALA, bringing a distinctive holistic health offering to the destination.

Designed by Heah & Co., with interiors by Studio Carter, Jayasom Wellness Resort AMAALA is located on Triple Bay’s largest cove and comprises 153 keys alongside 24 residences. The resort forms part of AMAALA’s secluded wellness core on the Red Sea coast, where nature and hospitality come together in a setting designed for reflection and renewal.

“As we launch the first Jayasom globally, we are bringing a new dimension to AMAALA’s wellness offering. Its dedicated, all-inclusive wellness retreats combine contemporary, evidence-based practices with Arab and Eastern healing traditions. Its personalized approach complements our ambition for AMAALA to become the world’s most comprehensive wellness destination supporting guests on their long-term health journeys in an exceptional natural environment,” said John Pagano, Group CEO of Red Sea Global.

The resort’s wellness philosophy brings together Arab and Eastern healing traditions alongside contemporary evidence-based practices, reflecting centuries of knowledge exchange across cultures, including contributions from pioneering scholars such as Ibn Sina (Avicenna). The offering spans holistic health, fitness, physiotherapy, nutrition, spa and beauty, supported by consultations, movement and daily activities. Each guest journey is tailored to individual goals including women’s health, couples and family wellbeing, as well as health, weight and lifestyle reset.

Nutrition is an integral part of the Jayasom Wellness Resort AMAALA experience, with a collection of eight dining venues designed to support balanced lifestyles. The resort's restaurants and cafés offer a diverse range of cuisines inspired by regional and international traditions, with an emphasis on fresh, seasonal ingredients and nutritious dishes. Complementing the dining offer are interactive culinary experiences and specialty concepts that encourage guests to explore the role of food in healthy living.

The resort is divided into an adults-only wellness offering and a dedicated experience for families. The adult-only zone provides a sanctuary focused on holistic therapies, physiotherapy, fitness and Pilates, while the family experiences feature age-specific facilities and activities designed to support connection, movement and healthy habits.

The Jayasom Residences comprise a limited collection of two- to four-bedroom beachfront villas, with private pools and expansive sea-facing terraces. Located adjacent to the resort, residents enjoy exclusive privileges such as complimentary wellness retreats, preferred access to treatments and dining, and invitations to Jayasom events worldwide.

Nestled between the Red Sea and the dramatic Tabuk mountains, the resort is surrounded by coastal landscapes providing opportunities for land and water-based activities. This includes hiking, trail running, cycling, kayaking, stand-up paddleboarding, snorkeling and diving.

Along with the rest of the destination, Jayasom Wellness Resort AMAALA is fully powered by solar energy. It also supports the destination’s ambition to achieve a 30% net conservation gain by 2040.

Jayasom AMAALA is the seventh resort to open at AMAALA, marking another milestone in the destination’s phased delivery. In the coming months, a further two resorts will join a growing portfolio of world-class hospitality brands, alongside branded residences, integrated wellness facilities, a marina, curated retail, a marine life experiential institute and destination dining.

About Red Sea Global

Red Sea Global (RSG) is a vertically integrated real estate developer with a diverse portfolio across tourism, residential, experiences, infrastructure, transport, healthcare, and services. This includes the luxury regenerative tourism destinations The Red Sea, which began welcoming guests in 2023, and AMAALA, which welcomed its first guests in 2026.

A third destination, Thuwal Private Retreat, opened in 2024. RSG was also entrusted with development works at AlWajh International Airport, focused on upgrading the terminal and infrastructure.

RSG is a PIF company and a cornerstone of Saudi Arabia’s ambition to diversify its economy. Across its growing portfolio of destinations, subsidiaries, and businesses, RSG seeks to lead the world toward a more sustainable future, showing how responsible development can uplift communities, drive economies, and enhance the environment.

About AMAALA

AMAALA is an unparalleled ultra-luxury wellness destination along the northwestern coast of the Red Sea in Saudi Arabia. Seamlessly blending sea, sun, sports, arts, and culture for an exceptional experience, it is one of the world’s most anticipated destinations developed by Red Sea Global (RSG) with regeneration at its core.

AMAALA officially opened its first resort in summer of 2026, with more than 1,600 hotel rooms set to open across nine different resorts complemented by high-end retail and fine dining experiences upon completion. The destination’s state-of-the-art wellness and spa facilities will offer a comprehensive array of multi-generational programs, services, and various therapies, customized by practitioners and centers pioneering in various medical and wellness fields for a more personalized wellness journey.

Influenced by AMAALA’s natural beauty and the purity of the Red Sea, the destination is where sustainability meets luxury. The aim of AMAALA is to offer the most comprehensive health and wellness experience that will help improve the wellbeing of its guests and community, helping them flourish and thrive.

Two of AMAALA’s hallmark features include Corallium Marine Life Institute, an educational and scientific research center, and the AMAALA Yacht Club, destined to become an international hub for luxury yachting.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260916231950/en/

Permalink

https://aetoswire.com/en/news/1609202657362

Contacts

For more information, please contact:

Arwa Alsantli, Manager - Public Relations

+966 56 616 6017

Arwa.Alsantli@RedSeaGlobal.com

 

Alushibe Holding Group inaugure un nouveau siège emblématique au cœur de Benghazi

BENGHAZI, Libye - mardi, 15. septembre 2026

La branche d’ingénierie du groupe, Arcadia, réalise ce projet emblématique de 45 000 pieds carrés, qui constitue le premier projet d’un portefeuille de projets de 7,15 millions de pieds carrés prévu pour la ville.

 

Alushibe Holding Group, l’un des plus grands groupes diversifiés de Libye et l’un des principaux employeurs privés du pays, a annoncé aujourd’hui l’inauguration officielle de son nouveau siège mondial dans le quartier de Beloun, à Benghazi. Ce bâtiment emblématique marque une étape majeure dans l’engagement à long terme du groupe envers la ville et dans son rôle continu dans la reconstruction de Benghazi.

Conçu et construit par Arcadia Engineering Consultancy, qui fait partie de la division Ingénierie et Infrastructures d’Alushibe Holding Group, le siège s’étend sur 45 000 pieds carrés d’espaces de travail et accueille plus de 70 membres de l’équipe dirigeante du groupe, ainsi que des dizaines de visiteurs et de partenaires venus du monde entier chaque jour. Il s’agit du premier projet achevé dans le cadre d’un portefeuille plus vaste de projets représentant 7,15 millions de pieds carrés que le groupe prévoit de développer à travers Benghazi.

Baptisé Alushibe Headquarters, le bâtiment réunit design avant-gardiste, innovation technologique et infrastructures de pointe. Ses espaces de travail modernes, ses espaces verts, ses lieux de loisirs, ainsi que ses services et équipements sur site, permettent de créer un environnement de travail de classe mondiale pensé pour répondre aux exigences de l’avenir du travail, et s’impose comme une nouvelle addition dynamique au quartier de Beloun.

« Depuis plus de 18 ans, Alushibe Holding Group est profondément implanté à Benghazi », a déclaré Ahmed Gadalla, Président du conseil d’administration d’Alushibe Holding Group. « L’inauguration de notre siège ne représente pas seulement un investissement majeur dans cette ville, mais témoigne également de notre engagement envers nos partenaires et nos clients à travers le monde. En créant des environnements de travail de classe mondiale où nos collaborateurs peuvent s’épanouir, nous renforçons notre capacité à poursuivre notre expansion, à soutenir davantage l’économie locale et à servir nos clients en Libye comme à l’échelle internationale ».

Un engagement en faveur de l’économie de Benghazi

Alushibe Holding Group demeure l’un des principaux employeurs de Benghazi, avec plus de 6 000 employés répartis dans six divisions. À travers Arcadia et l’ensemble de ses activités, Alushibe Holding Group poursuit ses investissements dans les secteurs de l’industrie, de la santé, du commerce et des destinations. Ces investissements couvrent notamment de grandes installations industrielles, des hôpitaux, des centres commerciaux, des projets mixtes, ainsi que des infrastructures dédiées à l’hôtellerie et au divertissement.

Une composante d’un investissement plus large dans la ville

Dans le cadre du projet de développement de son siège, Alushibe Holding Group a entrepris la modernisation des infrastructures du quartier environnant, en lançant notamment des travaux de réaménagement des rues et des trottoirs de Beloun, afin d’améliorer l’accessibilité et de valoriser davantage le quartier. Le groupe a également investi dans la rénovation et l’agrandissement des bureaux de ses filiales à travers la Libye, ainsi que dans certains sites internationaux.

À propos d’Alushibe Holding Group

Alushibe Holding Group est un groupe holding libyen diversifié dont le siège est établi à Benghazi et qui dispose d’un bureau à Dubaï. Fort d’activités commerciales remontant à 2008, le groupe opère à travers six divisions : biens de consommation, commerce de détail et destinations, industrie, santé, ingénierie et infrastructures, et services. Il emploie plus de 6 000 personnes et sert des millions de clients. Le groupe développe des usines, des destinations commerciales, des établissements de santé et des infrastructures qui permettent de renforcer l’économie libyenne et à soutenir la croissance nationale à long terme.

 

 

Permalink
https://www.aetoswire.com/fr/news/alsg15072026f

Contacts

Mohammed Gadalla

mohammed@alushibe.com